US 11,926,596 B2
Inhibitors of Rho associated coiled-coil containing protein kinase
Eduardas Skucas, Medford, MA (US); Kevin G. Liu, West Windsor, NJ (US); Ji-In Kim, Princeton, NJ (US); Masha V. Poyurovsky, New York, NY (US); Rigen Mo, Livingston, NJ (US); and Jingya Zhang, Great Neck, NY (US)
Assigned to Kadmon Corporation, LLC, Bridgewater, NJ (US)
Appl. No. 16/632,659
Filed by KADMON CORPORATION, LLC, New York, NY (US)
PCT Filed Jul. 23, 2018, PCT No. PCT/US2018/043331
§ 371(c)(1), (2) Date Jan. 21, 2020,
PCT Pub. No. WO2019/018853, PCT Pub. Date Jan. 24, 2019.
Claims priority of provisional application 62/535,603, filed on Jul. 21, 2017.
Prior Publication US 2021/0163421 A1, Jun. 3, 2021
Int. Cl. C07D 231/56 (2006.01); A61P 19/04 (2006.01); A61P 25/28 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01)
CPC C07D 231/56 (2013.01) [A61P 19/04 (2018.01); A61P 25/28 (2018.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01)] 18 Claims
 
1. A compound having the formula III:

OG Complex Work Unit Chemistry
wherein:
R1 is selected from the group consisting of lower alkyl, C3-C6 cycloalkyl, and R10O(CH2)2 wherein R10 is methyl;
R2 is phenyl or pyridyl, each of which may be unsubstituted or optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, hydroxy, lower alkyl, lower alkoxy, nitro, cyano, C1-C3 perfluoro alkyl, C1-C3 perfluoro alkoxy, carboxyl, RR′N—, RR′NCO—, RCONH—, RCONR′—, RO2C—, aryl-O— and heteroaryl-O—;
R3 is selected from H, lower alkyl, substituted lower alkyl, and RR′N—(C2-4 alkyl)-; and
each R and R′ is independently selected from H, lower alkyl, and C3-C6 cycloalkyl, or alternatively, R and R′ taken together form a 5 to 6 membered heterocyclic ring;
wherein substituted lower alkyl is a C1-4 alkyl having from one to three substituents independently selected from halo, hydroxy, lower alkoxy, amino, nitro, cyano, perfluoro lower alkyl, perfluoro lower alkoxy and carboxyl;
or a pharmaceutically acceptable salt thereof.